#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	11866	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2068	560.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1447	1447	C	678	C,G	661,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21762	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3584	594.6	0	.	n	.	0	T695C	SNP	695	695	T	983	983	C	682	C	665	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21762	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3584	594.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2259	2259	C	650	C	630	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21762	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3584	594.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2333	2333	A	657	A	632	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21762	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3584	594.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2885	2885	C	676	C	648	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1260	folP	855	855	100.0	folP.l15.c30.ctg.1	1636	75.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1075	1077	AGC	134;135;135	A;G;C	131;132;131	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3756	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3457	106.4	1	SNP	p	S91F	1	.	.	271	273	TTC	569	571	TTC	131;132;131	T;T;C	128;128;126	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3756	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3457	106.4	1	SNP	p	G95N	0	.	.	283	285	GGC	581	583	GGC	133;132;132	G;G;C	130;129;127	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3756	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3457	106.4	1	SNP	p	D95G	1	.	.	283	285	GGC	581	583	GGC	133;132;132	G;G;C	130;129;127	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1060	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1320	78.0	1	SNP	p	G45D	0	.	.	133	135	GGC	451	453	GGC	124;124;124	G;G;C	121;120;119	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	546	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1047	50.9	0	.	n	.	0	A197.	DEL	197	197	A	623	623	A	119	A	115	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4472	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3216	136.2	1	SNP	p	D86N	0	.	.	256	258	GAC	708	710	GAC	163;163;165	G;A;C	157;152;161	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4472	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3216	136.2	1	SNP	p	R87W	0	.	.	259	261	CGT	711	713	CGT	165;165;168	C;G;T	161;159;157	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4472	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3216	136.2	1	SNP	p	R87I	0	.	.	259	261	CGT	711	713	CGT	165;165;168	C;G;T	161;159;157	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4472	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3216	136.2	1	SNP	p	S87R	1	.	.	259	261	CGT	711	713	CGT	165;165;168	C;G;T	161;159;157	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4472	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3216	136.2	1	SNP	p	S88P	0	.	.	262	264	TCC	714	716	TCC	166;169;170	T;C;C	158;161;161	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2652	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2521	102.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1462	1464	GGC	144;144;145	G;G;C	142;143;140	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.35.001	penA.35.001	1	1	27	2616	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2379	106.6	1	SNP	p	A311V	0	.	.	931	933	GCC	1216	1218	GCC	153;152;153	G;C;C,A	148;148;147,1	penA.35.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	2616	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2379	106.6	1	SNP	p	I312M	1	.	.	934	936	ATG	1219	1221	ATG	151;151;151	A;T;G	147;147;143	penA.35.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	2616	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2379	106.6	1	SNP	p	V316T	1	.	.	946	948	ACC	1231	1233	ACC	147;147;148	A;C;C	140;146;146	penA.35.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	2616	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2379	106.6	1	SNP	p	T316P	0	.	.	946	948	ACC	1231	1233	ACC	147;147;148	A;C;C	140;146;146	penA.35.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	2616	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2379	106.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1732	1734	ACC	125;125;124	A;C;C	120;121;120	penA.35.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	2616	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2379	106.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1786	1788	GCG	119;116;117	G;C;G	111;101;102	penA.35.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	2616	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2379	106.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1786	1788	GCG	119;116;117	G;C;G	111;101;102	penA.35.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	2616	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2379	106.6	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1909	1911	GGT	104;104;105	G;G;T	102;100;101	penA.35.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	2616	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2379	106.6	1	SNP	p	G545S	0	.	.	1633	1635	GGC	1918	1920	GGC	100;102;102	G,A;G;C	96,1;98;99	penA.35.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	2616	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2379	106.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1936	1938	CCG	79;79;75	C,G;C;G	72,2;71;61	penA.35.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4236	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3112	133.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1559	1561	CCG	129;130;131	C;C;G	117;124;123	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1988	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1854	104.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	545	545	C	156	C,G	147,1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	190	porB1a	984	221	90.95	porB1a.l15.c30.ctg.2	326	17.6	0	.	p	.	0	S271T	NONSYN	811	813	TCG	48	50	ACT	33;32;31	A;C;T	23;25;25	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	190	porB1a	984	221	90.95	porB1a.l15.c30.ctg.2	326	17.6	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	54	56	GAT	29;27;26	G;A;T	26;26;25	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	190	porB1a	984	221	90.95	porB1a.l15.c30.ctg.2	326	17.6	0	.	p	.	0	D276N	NONSYN	826	828	GAT	63	65	AAC	26;27;27	A;A;C	26;27;26	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	190	porB1a	984	221	90.95	porB1a.l15.c30.ctg.2	326	17.6	0	.	p	.	0	N277H	NONSYN	829	831	AAC	66	68	CAC	27;27;27	C;A;C	27;27;27	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	190	porB1a	984	221	90.95	porB1a.l15.c30.ctg.2	326	17.6	0	.	p	.	0	R307E	NONSYN	919	921	AGA	156	158	GAA	13;13;13	G;A;A	13;13;13	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	190	porB1a	984	221	90.95	porB1a.l15.c30.ctg.2	326	17.6	0	.	p	.	0	T311A	NONSYN	931	933	ACA	168	170	GCA	14;14;14	G;C;A	14;14;14	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	190	porB1a	984	221	90.95	porB1a.l15.c30.ctg.2	326	17.6	0	.	p	.	0	E312D	NONSYN	934	936	GAA	171	173	GAC	13;13;13	G;A;C	12;13;13	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	190	porB1a	984	221	90.95	porB1a.l15.c30.ctg.2	326	17.6	0	.	p	.	0	F314I	NONSYN	940	942	TTC	177	179	ATC	14;14;14	A;T;C	14;13;14	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	190	porB1a	984	221	90.95	porB1a.l15.c30.ctg.2	326	17.6	0	.	p	.	0	A316S	NONSYN	946	948	GCG	183	185	TCG	13;14;14	T;C;G	13;14;14	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	190	porB1a	984	221	90.95	porB1a.l15.c30.ctg.2	326	17.6	0	.	p	.	0	V318A	NONSYN	952	954	GTC	189	191	GCC	14;14;13	G;C;C	14;14;13	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	190	porB1a	984	221	90.95	porB1a.l15.c30.ctg.2	326	17.6	0	.	p	.	0	G319S	NONSYN	955	957	GGC	192	194	AGC	13;13;13	A;G;C	13;13;13	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	190	porB1a	984	221	90.95	porB1a.l15.c30.ctg.2	326	17.6	0	.	p	.	0	G320A	NONSYN	958	960	GGT	195	197	GCC	13;13;13	G;C;C	12;13;12	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	190	porB1a	984	221	90.95	porB1a.l15.c30.ctg.2	326	17.6	0	.	p	.	0	G322V	NONSYN	964	966	GGT	201	203	GTT	13;13;14	G;T;T	13;13;14	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2236	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	1738	126.3	0	.	p	.	0	E38K	NONSYN	112	114	GAA	403	405	AAA	177;181;181	A;A;A	172;176;176	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2236	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	1738	126.3	0	.	p	.	0	I45V	NONSYN	133	135	ATT	424	426	GTT	177;178;177	G;T;T	174;175;175	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2236	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	1738	126.3	0	.	p	.	0	G48E	NONSYN	142	144	GGA	433	435	GAA	178;179;181	G;A;A	177;178;179	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2236	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	1738	126.3	1	SNP	p	G120K	1	.	.	358	360	AAG	649	651	AAG	164;162;161	A,C;A;G	155,2;159;148	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2236	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	1738	126.3	1	SNP	p	N121D	0	.	.	361	363	AAC	652	654	AAC	162;162;165	A;A;C,A	156;156;156,1	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2236	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	1738	126.3	1	SNP	p	A121N	1	.	.	361	363	AAC	652	654	AAC	162;162;165	A;A;C,A	156;156;156,1	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8168	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4849	165.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	882	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	948	90.3	1	SNP	p	V57M	1	.	.	169	171	ATG	504	506	ATG	183;183;181	A;T;G	177;175;176	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
